Date: 2017-04-17
Type of information: Services contract
Compound: custom assay for the detection of mRNA targets using the HTG EdgeSeq technology
Company: HTG Molecular Diagnostics (USA - AZ) Daiichi Sankyo (Japan)
Therapeutic area: Cancer - Oncology - Technology - Services
Type agreement: services
Action mechanism:
Disease:
Details:
- • On April 17, 2017, HTG Molecular Diagnostics, a provider of instruments, reagents and services for molecular profiling applications, announced that it has entered into a master services agreement with Daiichi Sankyo for work to be performed in HTG’s VERI/O laboratory. The initial project includes the development of a custom assay for the detection of nearly 3,000 mRNA targets using the HTG EdgeSeq technology. When completed, the custom assay will be used to generate data from formalin-fixed, paraffin-embedded (FFPE) samples. Daiichi Sankyo plans to use these data to identify a tumor profiling assay for future studies under the agreement. Daiichi Sankyo also has engaged HTG to process several hundred FFPE samples using the HTG EdgeSeq ALKPlus Assay EU in a research use only mode for exploratory research on new, potential therapeutic biomarkers.
Financial terms:
Latest news:
Is general: Yes
